期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺癌靶向治疗研究进展 被引量：4

原文传递
导出
摘要 甲状腺癌组织学类型主要包括乳头状癌（PTC）、滤泡状癌（FTC）、髓样癌（MTC）和未分化甲状腺癌（ATC）,PTC为主要类型,约占80％.目前甲状腺癌的常规治疗方式有外科手术、放射碘治疗和促甲状腺素抑制疗法[1].面对难治性甲状腺癌包括髓样癌、未分化癌和分化型甲状腺癌（DTC）,常规治疗方法均难以取得满意的疗效.近年来以分子标志物为指导的患者个体化治疗和靶向治疗药物的不断涌现为这一难题提供了新的希望.现针对甲状腺癌的分子靶向治疗进展进行综述.
作者 陈晓意 林晓东 杜嘉林 赵刚 吴泽宇
机构地区 汕头大学医学院 广东省人民医院(广东省医学科学院)普外二区
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第4期939-940,共2页 Chinese Journal of Experimental Surgery
基金 广东省科技计划资助项目（20118031800387）
关键词 未分化甲状腺癌 分子靶向治疗 分化型甲状腺癌 靶向治疗药物 组织学类型 促甲状腺素 个体化治疗 分子标志物
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thy- roid cancer [ J ]. Thyroid, 2009,19 ( 11 ) : 1167-1214.
  • 2Fagin JA. How thyroid tumors start and why it matters :kinase mutants as targets for solid cancer pharmacotherapy [ J ]. J Endocrinol, 2004, 183 (2) :249-256.
  • 3Vieira JM, Santos SC, Espadinha C, et al. Expression of vascular endo- thelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin : a potential autocrine loop [ J ]. Eur J Endocrino, 2005,153 (5) :701-709.
  • 4Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sor- afenib in metastatic medullary thyroid cancer[ J]. J Clin Onco1,2010, 28(14) :2323-2330.
  • 5Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a ran- domized, double-blind phase III trial [ J ]. J Clin Onco1,2012,30 (2) : 134-141.
  • 6Perez CA, Arango BA, Velez M, et al. Emerging role of multikinase in- hibitors for refractory thyroid cancer[ J ]. Biologics ,2012,6:257-265.
  • 7Elisei R, Schlumberger MJ, Mtiller SP, et al. Cabozantinib in progres- sive medullary thyroid cancer[ J]. J Clin Oncol,2013,31 (29) :3639- 3646.
  • 8van Dijk D, Plukker JT, van der Horst-Sehrivers AN, et al. The value of detectable thyroglobulin in patients with differentiated thyroid canc- er after initial 131I therapy[ J]. Clin Endoerinol (Oxf) ,2011,74( 1 ) : 104-110.
  • 9Pelttari H, Valimaki MJ, Ltiyttyniemi E, et al. Post-ablative serum thy- roglobulin is an independent predictor of recurrence in low-risk differ- entiated thyroid carcinoma: a 16-year follow-up study [ J ]. Eur J Endo-crinol,2010,163 (5) :757-763.
  • 10Brose MS, Nutting CM,Jarzab B, et al. Sorafenib in radiactive iodine- refractory, locally advanced or me tastatic differetiated thyroid cancer: a randornised, double-blind, phase 3 trail [ J ]. Lancet, 2014, 384 ( 9940 ) : 60421-60429.

二级参考文献47

  • 1范正军,吴阳,张志永,李德旭,王陆林,谢志徵.雌激素受体表达和微血管密度改变在肝门部胆管癌中的意义[J].中华实验外科杂志,2005,22(8):950-951. 被引量：7
  • 2李咏梅,曹芳,曹新.乳腺癌RASSF1A基因表达及启动子区甲基化研究[J].南京医科大学学报（自然科学版）,2006,26(7):496-500. 被引量：9
  • 3李敏,黄在菊,董卫红,李晓艳,王晓翊,贺晓红,王瀚,王泽华.卵巢上皮性癌组织中p16INK4A基因表达缺陷的意义及其与甲基化的关系[J].中华妇产科杂志,2006,41(6):408-412. 被引量：8
  • 4Das PM,Singal R.DNA methylation and cancer.J Clin Oncol,2004,22:46324642.
  • 5Xing M,Usadel H,Cohen Y,et al.Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors-a marker of malignancy and a cause of gene silencing.Cancer Res,2003,63:2316-2321.
  • 6Xing M,Cohen Y,Mambo E,et al.Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.Cancer Res,2004,64:1664-1668.
  • 7Boltze C,Zack S,Quednow C,et al.Hypermethylation of the CDKN2/ pl6 INK4 A promoter in thyroid carcinogenesis.Pathol Res Pract,2003,199=399404.
  • 8Smith JA,Fan CY,Zou C,et al.Methylation status of genes in papillary thyroid carcinoma.Arch Otolaryngol Head Neck Surg,2007,133:1006-1011.
  • 9Schagdarsurengin U,Gimm O,Dralle H,et al.CpC island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.Thyroid,2006,16:633-642.
  • 10Schagdarsuregin U,Gimm O,Hoang-Vu C,et al.Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.Cancer Res,2002,62:3698-3701.

共引文献23

同被引文献30

引证文献4

二级引证文献12

中华实验外科杂志
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部